Activation-induced T cell apoptosis by monocytes from stem cell products

International Immunopharmacology

Volumn 1, Issue 7, 2001, Pages 1307-1319

  Ino, Kazuhiko ^a   Ageitos, Ana G ^b   Singh, Rakesh K ^c   Talmadge, James E ^c  

^a NAGOYA UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^b Instituto Reina Sofía de Investigación Nefrológica   (Spain)

^c UNIVERSITY OF NEBRASKA MEDICAL CENTER   (United States)

Author keywords

IL 2; Mitogenesis; Monocytes; Peripheral tolerance; T cells

Indexed keywords

CD14 ANTIGEN; CD56 ANTIGEN; CELL DNA; INTERLEUKIN 2; MONOCLONAL ANTIBODY CD3; PHYTOHEMAGGLUTININ;

APHERESIS; APOPTOSIS; ARTICLE; BREAST CANCER; CELL ACTIVATION; CELL COUNT; CELL CYCLE; CELL FUNCTION; CELL INTERACTION; CLINICAL ARTICLE; CONTROLLED STUDY; HUMAN; HUMAN CELL; IMMUNOLOGICAL TOLERANCE; IRRADIATION; LYMPHOCYTE FUNCTION; LYMPHOCYTE PROLIFERATION; MITOGENESIS; MONOCYTE; NATURAL KILLER CELL; NONHODGKIN LYMPHOMA; PERIPHERAL BLOOD STEM CELL; PRIORITY JOURNAL; STEM CELL TRANSPLANTATION; T LYMPHOCYTE; T LYMPHOCYTE ACTIVATION;

ANTIBODIES, MONOCLONAL; ANTIGENS, CD3; APOPTOSIS; CELL DIVISION; FLOW CYTOMETRY; FLUORESCENT ANTIBODY TECHNIQUE; HUMANS; INTERLEUKIN-2; MONOCYTES; PHYTOHEMAGGLUTININS; STEM CELLS; T-LYMPHOCYTES; TUMOR STEM CELLS;

EID: 0035005380     PISSN: 15675769     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1567-5769(01)00062-5     Document Type: Article

References (55)

1. High-dose cyclophosphamide, carmustine, and etoposide followed by autologous peripheral stem cell transplantation for patients with relapsed Hodgkin's disease
2. High-dose chemotherapy and autologous hematopoietic stem-cell transplantation for aggressive non-Hodgkin's lymphoma
3. Granulocyte colony-stimulating factor "mobilized" peripheral blood progenitor cells accelerate granulocyte and platelet recovery after high-dose chemotherapy
4. Immune reconstitution following peripheral blood stem cell transplantation, autologous bone marrow transplantation and allogeneic bone marrow transplantation
5. Immunologic attributes of cytokine mobilized peripheral blood stem cells and recovery following transplantation
6. Immunologic phenotype and function in human bone marrow, blood stem cells and umbilical cord blood
7. Antifungal effects of yeast-derived rhu-GM-CSF in patients receiving high-dose chemotherapy given with or without autologous stem cell transplantation: A retrospective analysis
8. Immune reconstitution following high-dose chemotherapy with stem cell rescue in patients with advanced breast cancer
9. Increased apoptosis of peripheral blood T cells following allogeneic hematopoietic cell transplantation
10. Immune reconstitution after bone marrow transplantation for combined immunodeficiencies: Down-modulation of Bcl-2 and high expression of CD95/Fas account for increased susceptibility to spontaneous and activation-induced lymphocyte cell death
11. Prolonged CD4 depletion after sequential autologous peripheral blood progenitor cell infusions in children and young adults
12. Longitudinal monitoring of immune reconstitution by CDR3 size spectratyping after T-cell-depleted allogeneic bone marrow transplant and the effect of donor lymphocyte infusions on T-cell repertoire
13. Rapid immunologic reconstitution following transplantation with mobilized peripheral blood stem cells as compared to bone marrow
14. Autologous peripheral blood stem cell transplantation: Analysis of autografted cells and lymphocyte recovery
15. Immunological reconstitution after high dose chemotherapy and autologous blood stem cell transplantation for advanced ovarian cancer
16. Altered immunologic reconstitution after standard-dose chemotherapy or high-dose chemotherapy with autologous bone marrow support
17. Monocytes from mobilized stem cells inhibit T cell function
18. + T-cell apoptosis following stem cell transplantation
19. Potential for cytokine and product manipulation to improve the results of autologous transplantation for rheumatoid arthritis
20. Restoration of T and NK cell function in GM-CSF mobilized stem cell products from breast cancer patients by monocyte depletion
21. IL-2 expansion of T and NK cells from growth factor-mobilized peripheral blood stem cell products: Monocyte inhibition
22. Comparison of monocyte-dependent T cell inhibitory activity in GM-CSF vs. G-CSF mobilized PSC products
23. Impaired T and NK cell response of bone marrow and peripheral blood stem cell products to interleukin (IL)-2
24. Transplantation of allogeneic peripheral blood stem cells mobilized by recombinant human granulocyte colony-stimulating factor
25. Allogeneic blood stem cell transplantation for refractory leukemia and lymphoma: Potential advantage of blood over marrow allografts
26. Detection and management of bone marrow micrometastases in breast cancer
27. Cyclophosphamide-induced suppressor cells in mice: Suppression of the antibody response in vitro and characterization of the effector cells
28. + T cell-dependent tumor rejection
29. Proliferation of human peripheral blood lymphocytes induced by recombinant human interleukin-2: Contribution of large granular lymphocytes and T lymphocytes
30. Use of anti-CD3 monoclonal antibody in the generation of effector cells from human solid tumors for use in cancer biotherapy
31. Evaluation of glucocorticoid-induced DNA fragmentation in mouse thymocytes by flow cytometry
32. Natural suppressor (NS) cells, members of the LGL regulatory family
33. T-cell subsets and suppressor cells in human bone marrow
34. Studies of CD4-CD8-alpha/beta bone marrow T-cells with suppressor activity
35. Characterization of natural suppressor cell populations in adult rat bone marrow
36. Mechanism of protection from graft-vs.-host disease in murine mixed allogeneic chimeras: I. Development of a null cell population suppressive of cell-mediated lympholysis responses and derived from the syngeneic bone marrow component
37. + cells in cancers that secrete granulocyte/macrophage colony-stimulating factor
38. Stimulation of immune-suppressive bone marrow cells by colony-stimulating factors
39. Differential induction of prostaglandin E2-dependent and-independent immune suppressor cells by tumor-derived GM-CSF and M-CSF
40. Indomethacin sensitive suppressor-cell activity in head and neck cancer patients. The role of the adherent mononuclear cell
41. Contribution of monocytes to the decreased lymphoproliferative response to phytohemagglutinin in patients with lung cancer
42. Peripheral blood T cells generated after allogeneic bone marrow transplantation: Lower levels of bcl-2 protein and enhanced sensitivity to spontaneous and CD95-mediated apoptosis in vitro. Abrogation of the apoptotic phenotype coincides with the recovery of normal naive/primed T-cell profiles
43. Functional consequences of IL-2-receptor expression on resting human lymphocytes: Identificaiton of a novel NK-cell sub-set with high-affinity receptors
44. The IL-2 receptor complex: Its structure, function, and target genes
45. A macrophage-derived factor that inhibits the production and action of interleukin-2
46. Suppressor macrophages in African trypanosomiasis inhibit T cell proliferative responses by nitric oxide and prostaglandins
47. Molecular basis of "suppressor" macrophages. Arginine metabolism via the nitric oxide synthetase pathway
48. Nitric oxide production is required for murine resident peritoneal macrophages to suppress mitogen-stimulated T cell proliferation. Role of IFN-gamma in the induction of the nitric oxide-synthesizing pathway
49. The role of tumor necrosis factor, interferon-gamma, transforming growth factor-beta, and nitric oxide in the expression of immunosuppressive functions of splenic macrophages induced by Mycobacterium avium complex infection
50. Monocytes are required to prime peripheral blood T cells to undergo apoptosis
51. A subclass of dendritic cells kills CD4 T cells via Fas/Fas-ligand-induced apoptosis
52. Selective activation-induced apoptosis of peripheral T cells imposed by macrophages: A potential mechanism of antigen-specific peripheral lymphocyte deletion
53. T cells commit suicide, but B cells are murdered!
54. Fas (CD95)/FasL interactions required for programmed cell death after T-cell activation
55. Fas ligand mediates activation-induced cell death in human T lymphocytes